These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 9051240)

  • 1. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
    Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
    Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
    Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
    Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
    Brandt SJ; Peters WP; Atwater SK; Kurtzberg J; Borowitz MJ; Jones RB; Shpall EJ; Bast RC; Gilbert CJ; Oette DH
    N Engl J Med; 1988 Apr; 318(14):869-76. PubMed ID: 3281007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy].
    Richel DJ; Baars JW; Wijngaarden MJ; van der Schoot CE; Vlasveld LT; Rodenhuis S
    Ned Tijdschr Geneeskd; 1993 Jan; 137(5):245-50. PubMed ID: 7679478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
    Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
    Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
    Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A
    Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
    Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
    Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-CSF is a major component of colony-stimulating activity (CSA) in the plasma of patients with multiple myeloma after treatment with high-dose melphalan (HDM).
    Joffe JK; Bell JB; Denham S; Adshead F; Millar JL; Millar BC
    Exp Hematol; 1995 Apr; 23(4):376-82. PubMed ID: 7534716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
    Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P
    Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study.
    D'Hondt V; Guillaume T; Humblet Y; Doyen C; Chatelain B; Feyens AM; Staquet P; Osselaer JC; Müll B; Symann M
    Bone Marrow Transplant; 1994 Mar; 13(3):261-4. PubMed ID: 7515299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor.
    Kohno A; Takeyama K; Narabayashi M; Okamoto R; Adachi I; Tobinai K; Shimoyama M
    Bone Marrow Transplant; 1995 Jan; 15(1):49-54. PubMed ID: 7538002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.